Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms |
Action inhibitors |
Mechanism alpha-tubulin inhibitors(Tubulin alpha inhibitors), β-tubulin inhibitors(tubulin beta class I inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC71H114N8O19 |
InChIKeySMPBMEBFSPMGRU-AKHISFFYSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 27 Apr 2020 | |
Neoplasms | Preclinical | United States | 27 Apr 2020 |